Company Research Report: Precisis GmbH

Company Overview

• Name: Precisis GmbH

• Mission: Precisis aims to revolutionize brain function through innovative bioelectronic methods, creating therapies that can improve the quality of life for individuals with brain disorders.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Karl Stoklosa, CEO

• Michael Tittelbach, Chief Technical Officer

• Pedro Marques, Chief Commercial Officer

• Headquarters: Margot-Becke-Ring 8, 69124 Heidelberg, Germany

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Precisis is renowned for its innovative EASEE® system, a minimally invasive brain pacemaker designed to treat drug-resistant epilepsies.

Products

EASEE® System

• Description: The EASEE® system is a groundbreaking neurostimulation device that directs therapeutic currents to specified brain areas, effectively reducing epileptic seizures.

• Key Features:

• Minimally invasive with subcutaneous electrodes located outside the cranium.

• Utilizes AI-based learning models to activate or inhibit specific brain cells.

• Fully reversible implantation.

• CE-certified since September 15, 2022.

• Recent versions include EASEE® III with extended three-year battery life.

Recent Developments

• New Product Launches:

• In July 2024, EASEE® III was launched featuring an extended three-year battery life.

• New Features Added:

• Continued enhancement of AI capabilities for optimized personalized therapies.

• New Partnerships:

• Partnered with Cochlear Ltd in 2021 to leverage financial benefits and scientific expertise in medical implants.

• Clinical Studies:

• Initiated the EASEE4YOU study in May 2023 to assess device performance in children aged 12 to 17 with medicament-resistant epilepsy.

• The PEARL study, started in September 2024, to evaluate the long-term effects of the EASEE® brain stimulator.

• Market Expansions:

• EASEE® made available through the NHS in the United Kingdom as of May 2024.

• Partnership with Pagaimo Medical to introduce EASEE® in Portugal as of June 2024.

• Tech Recognition:

• Precisis secured second place at the HEALTH-i Award 2024, emphasizing its innovative contribution to health technology.

• Regulatory Milestones:

• Secured market approval for EASEE® in September 2022 which led to successful implantations across epilepsy centers in Germany, Austria, and Switzerland.

Additional Information

• Investment and Funding:

• Received financial support from BMBF (German Federal Ministry of Education and Research) for medical technology innovations.

• Majority funding during the start-up phase came from private investments.

• Company Vision:

• Precisis is dedicated to expanding the applications of its brain stimulation technology to treat additional conditions like depression and stroke.

• The company is actively working to bring the EASEE® system to broader European markets based on positive feedback and demands.

---

This report presents a comprehensive analysis of Precisis GmbH based on the provided information, showcasing its dedication to advancing neurostimulation therapies and expanding its market presence.